Treatable brain network biomarkers in children in coma using task and resting-state functional MRI: a case series
In this report, we present three cases in which multimodal brain network evaluation played a helpful role in patient care. This evaluation encompassed various assessments such as continuous video EEG, visual-evoked potentials, somatosensory-evoked potentials, auditory brainstem-evoked responses, resting-state functional MRI (rs-fMRI), and passive-based and command-based task-based fMRI. It is worth noting that the latter three evaluations are unique as they have not yet been established as part of the standard care protocol for assessing acute brain injuries in children with suppressed consciousness. The first patient unde...
Source: Frontiers in Neurology - August 10, 2023 Category: Neurology Source Type: research
Pharmacology in Treatment of Patients with Disorders of Consciousness
Pharmacologic treatment of disorders of consciousness remains a critical but challenging task for clinicians. Amantadine has been shown to promote the rate of neurologic recovery for patients with traumatic disorders of consciousness when administered between 4 and 16 weeks, as demonstrated by a well-designed randomized control trial. While there are no large, randomized controlled trials to support the use of other dopaminergic medicines (bromocriptine, levodopa, apomorphine), there is a large body of literature implicating their role in improving alertness an d responsiveness in disorders of consciousness. Zolpidem can...
Source: Physical Medicine and Rehabilitation Clinics of North America - August 1, 2023 Category: Rehabilitation Authors: Michael H. Marino Source Type: research
Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine
Background:After more than 2 years of the pandemic SARS-CoV-2, there is still a lack of a medications with satisfactory efficacy. Amantadine was hypothesized to be a potentially efefctive therapy. A retrospective, observational study was conducted to assess the incidence of COVID-19 in patients with Parkinson's disease (PD) taking amantadine and those who did not. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - August 1, 2023 Category: Neurology Authors: J. S ławek, F. Przytuła, J. Kasprzak, J. Dulski Source Type: research
Amantadine treatment in Parkinson ’s disease patients as a modulatory factor of SARS-Cov-2 infection
Background:Amantadine has been used for the prevention and treatment of viral influenza A, but more recently it is used mainly in PD patients. Previous studies showed a possible impact of amantadine on COVID-19 severity in patients using this drug due to other (neurological diseases, mainly PD). Therefore the aim of this study was to evaluate the possible impact of amantadine on the SARS-Cov-2 infection in Parkinson ’s disease (PD) patients. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - August 1, 2023 Category: Neurology Authors: S. Szlufik, A. Chudzik, A. Przybyszewski, D. Koziorowski Source Type: research
Clinical Practice Guideline: The Neurological Rehabilitation of Adults With Coma and Disorders of Consciousness
CONCLUSION: For the first time, evidence-based German-language clinical practice guidelines have now become available for the neurological rehabilitation of patients with DoC.PMID:37434290 | DOI:10.3238/arztebl.m2023.0159 (Source: Deutsches Arzteblatt International)
Source: Deutsches Arzteblatt International - July 12, 2023 Category: General Medicine Authors: Andreas Bender Bernd Eifert Ilona Rubi-Fessen Ralf J Jox Petra Maurer-Karattup Friedemann M üller Source Type: research
Amantadine toxicity causing visual hallucinations
We describe a woman with multiple sclerosis taking amantadine who developed acute renal impairment, which triggered florid visual hallucinations that resolved on stopping the medication.PMID:37419676 | DOI:10.1136/pn-2023-003723 (Source: Practical Neurology)
Source: Practical Neurology - July 7, 2023 Category: Neurology Authors: Jessica Marie Barbara Adrian Pace Source Type: research
Amantadine toxicity causing visual hallucinations
We describe a woman with multiple sclerosis taking amantadine who developed acute renal impairment, which triggered florid visual hallucinations that resolved on stopping the medication.PMID:37419676 | DOI:10.1136/pn-2023-003723 (Source: Practical Neurology)
Source: Practical Neurology - July 7, 2023 Category: Neurology Authors: Jessica Marie Barbara Adrian Pace Source Type: research
